Stomatitis News and Research

RSS

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

STRIVE study to assess safety, efficacy of rVSV-ZEBOV candidate Ebola vaccine

The Centers for Disease Control and Prevention (CDC), in partnership with the Sierra Leone College of Medicine and Allied Health Sciences and the Sierra Leone Ministry of Health and Sanitation, is now enrolling and vaccinating volunteers for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE).

15 Apr 2015

UTMB scientists develop quick-acting vaccine that is effective against Ebola strain

An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola strain that killed thousands of people in West Africa last year.

8 Apr 2015

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC).

6 Apr 2015

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

A live vaccine based on the "Vesicular Stomatitis Virus" (VSV) has yielded highly promising results for the rapid development of an effective vaccine against the Ebola virus. This vaccine would only need to be injected once for long-lasting immunoprotection.

2 Apr 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Large clinical trial to assess safety, efficacy of two experimental Ebola vaccines opens in Liberia

A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-U.S. clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Feb 2015

BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A., granting them the rights to promote, sell and market its own product GelX for the Middle East, Eastern Europe, Russia and North Africa.

19 Jan 2015

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations.

11 Dec 2014

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Dacomitinib, an irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor, does not improve outcomes compared with the first-generation EGFR–TKI erlotinib in patients with advanced non-small-cell lung cancer, irrespective of their KRAS mutation status, finds the ARCHER 1009 study.

24 Nov 2014

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.

24 Nov 2014

Toxicity profiles for everolimus, temsirolimus differ in advanced RCC

Non-infectious pneumonitis and stomatitis occur more frequently in patients with advanced renal cell carcinoma treated with everolimus than temsirolimus, whereas temsirolimus is associated with a higher incidence of fatigue, rash and asthenia, a retrospective study reports.

13 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Human trial of second investigational Ebola vaccine candidate under way

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center in Bethesda, Maryland.

23 Oct 2014

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40).

23 Oct 2014

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S.

6 Oct 2014

NIH to start initial human testing of investigational Ebola vaccine next week

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

29 Aug 2014

Zebrafish and virus help scientists map the living brain

A virus and a zebrafish are helping scientists map the living brain. "You can kinda draw a diagram and see how cells within it are connected in a functioning brain," said Dr. Albert Pan, neuroscientist at the Medical College of Georgia at Georgia Regents University.

26 Aug 2014